Natera $NTRA

Health Care · NASDAQ

$273.40
-16.52 (-5.70%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Nov 6, 2026, the first target we tracked for NTRA.

Natera (NTRA) is trading down at $273.40 (-5.70%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: July 2, 2015 · $18.00 offering · NASDAQ

Analyst price targets on NTRA

One firm's current price target on Natera: $500 — 83% above the current $273. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateNov 6, 2026 FirmCanaccord Genuity RatingBuy · reiterates Targetat $311 · $500 +61% Horizonby Nov 2027 StatusOpen

Entry price $311, the close nearest Nov 6, 2026, when the target was reported; the target is +61% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Nov 2027.

Scoring Open: judged on the close on Nov 6, 2027.

Source Canaccord reiterates Natera stock rating on strong Q3 results Investing.com · Nov 6, 2026 · opens the publisher's site
Canaccord Genuity reiterated a Buy rating and $500 price target on Natera Inc.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Natera revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.31B$879.2M−$547.8MFY2016 revenue: $217.1MFY2016 net income: −$100.3M · Net margin −46.2%'16FY2017 revenue: $210.9MFY2017 net income: −$137.6M · Net margin −65.2%'17FY2018 revenue: $257.7MFY2018 net income: −$128.2M · Net margin −49.7%'18FY2019 revenue: $302.3MFY2019 net income: −$124.8M · Net margin −41.3%'19FY2020 revenue: $391.0MFY2020 net income: −$229.7M · Net margin −58.8%'20FY2021 revenue: $625.5MFY2021 net income: −$471.7M · Net margin −75.4%'21FY2022 revenue: $820.2MFY2022 net income: −$547.8M · Net margin −66.8%'22FY2023 revenue: $1.08BFY2023 net income: −$434.8M · Net margin −40.2%'23FY2024 revenue: $1.70BFY2024 net income: −$190.4M · Net margin −11.2%'24FY2025 revenue: $2.31BFY2025 net income: −$208.2M · Net margin −9.0%'25−29.7%0%50%FY2016 net margin: −46.2% (off the scale, which stops at −29.7%)FY2017 net margin: −65.2% (off the scale, which stops at −29.7%)FY2018 net margin: −49.7% (off the scale, which stops at −29.7%)FY2019 net margin: −41.3% (off the scale, which stops at −29.7%)FY2020 net margin: −58.8% (off the scale, which stops at −29.7%)FY2021 net margin: −75.4% (off the scale, which stops at −29.7%)FY2022 net margin: −66.8% (off the scale, which stops at −29.7%)FY2023 net margin: −40.2% (off the scale, which stops at −29.7%)FY2024 net margin: −11.2%FY2025 net margin: −9.0%
Natera annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$217.1M$210.9M$257.7M$302.3M$391.0M$625.5M$820.2M$1.08B$1.70B$2.31B
Growth (year over year)+14.0%−2.8%+22.1%+17.3%+29.3%+60.0%+31.1%+32.0%+56.7%+35.9%
Gross profit$82.6M$75.4M$99.6M———————
Gross margin38.0%35.8%38.6%———————
Operating income−$101.0M−$135.3M−$114.6M−$116.3M−$216.3M−$468.2M−$541.0M−$446.2M−$222.3M−$309.9M
Operating margin−46.6%−64.2%−44.5%−38.5%−55.3%−74.8%−66.0%−41.2%−13.1%−13.4%
Net income−$100.3M−$137.6M−$128.2M−$124.8M−$229.7M−$471.7M−$547.8M−$434.8M−$190.4M−$208.2M
Net margin−46.2%−65.2%−49.7%−41.3%−58.8%−75.4%−66.8%−40.2%−11.2%−9.0%
EPS (diluted)−$1.95−$2.59−$2.22−$1.79−$2.84−$5.21−$5.57−$3.78−$1.53−$1.52
Balance sheet
Cash and equivalents$15.3M$12.6M$46.4M$61.9M$48.7M$84.4M$466.0M$642.1M$945.6M$1.08B
Total assets$210.7M$214.6M$268.2M$582.7M$932.2M$1.24B$1.39B$1.44B$1.66B$2.40B
Total liabilities$104.2M$189.2M$236.0M$303.9M$445.9M$583.2M$688.7M$676.4M$465.3M$685.9M
Long-term debt—————$280.4M$281.7M$282.9M——
Shareholders' equity$143.6M$25.4M$32.2M$278.7M$486.2M$653.3M$705.7M$765.3M$1.20B$1.71B
Cash flow
Operating cash flow−$74.1M−$97.8M−$70.6M−$63.4M−$182.5M−$335.2M−$431.5M−$247.0M$135.7M$215.3M
Capital expenditure$23.1M$9.87M$3.88M$4.97M$19.6M$41.0M$47.7M$39.2M$66.4M$106.2M
Free cash flow−$97.2M−$107.7M−$74.5M−$68.4M−$202.1M−$376.3M−$479.2M−$286.2M$69.2M$109.1M

From Natera's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Natera in the news

Nov 13, 2026 Investing.com Natera co-founder Sheena sells $478,944 in common stock
Nov 10, 2026 Investing.com Natera director Jonathan Sheena sells $995,404 in stock
Nov 6, 2026 Investing.com Canaccord reiterates Natera stock rating on strong Q3 results Target
Sep 28, 2026 Benzinga Hewlett Packard, Natera, UnitedHealth Group: CNBC ‘Final Trades’ - UnitedHealth Group (NYSE:UNH)

About Natera

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women's health, cancer, and organ health. Natera's proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.

Source: Wikipedia — Natera

Headquarters
Austin, Texas From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →